This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The SGLT2 inhibitor dapagliflozin was superior to standard care alone in decreasing rates of all-cause mortality or worsening heart failure (HF) in older adults with aortic stenosis undergoing TAVI, resulting in a 28% relative risk reduction, according to results from the DAPA-TAVI study presented during a Late-Breaking Clinical Trial session during ACC.25 in Chicago and simultaneously published in the NEJM.
Intravascular lithotripsy (IVL) may have once been synonymous with Shockwave Medical, but its now rapidly becoming one of the hottest segments in interventional cardiology, spurred on by Abbotts new IVL Investigational Device Exemption (IDE) from the FDA. IVL is a minimally invasive medical catheter-based procedure that treats calcified plaque in blood vessels.
After stent implantation, a three-month regimen of dual antiplatelet therapy (DAPT) was more effective than a one-month regimen at reducing adverse events without increasing bleeding risk in patients with a high bleeding risk (HBR), according to a Late-Breaking Clinical Trial presented at ACC.25 in Chicago. Furthermore, in patients with a low bleeding risk (LBR), a three-month regimen was found to be superior to 12 months for reducing bleeding risk and comparable in reducing adverse events.
(MedPage Today) -- CHICAGO -- Semaglutide further solidified its efficacy for diabetes-associated cardiovascular conditions, this time building its positions in peripheral artery disease (PAD) and with an oral formulation, based on two major.
Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
Publication date: Available online 29 March 2025 Source: The American Journal of Cardiology Author(s): Thomas R. Basala, Muhmmad S. Khalid, Ozgur Selim Ser, Michael Megaly, Matthew Glogoza, Dimitrios Strepkos, Athanasios Rempakos, Michaella Alexandrou, Deniz Mutlu, Pedro Carvalho, Sydney Peng, Olga Mastrodemos, Sandeep Jalli, Judit Karacsonyi, Yader Sandoval, Yale Wang, Patsa Sullivan, David J.
Rivaroxaban was found to be as effective and safe as warfarin in resolving post myocardial infarction (MI) left ventricular (LV) thrombus at three months, according to a Late-Breaking Clinical Trial presented at ACC.25 in Chicago.
A secondary analysis of FINEARTS-HF found consistent efficacy of finerenone on heart failure events and cardiovascular death, irrespective of AF status.
This secondary analysis of the Finerenone Trial to Investigate Efficacy and Safety Superior to Placebo in Patients With Heart Failure (FINEARTS-HF) randomized clinical trial investigates the breakdown of cause-specific mortality in patients with heart failure and mildly reduced or preserved ejection fraction and if this mortality is modified by finerenone.
The investigational drug lorundrostat led to a significant reduction in systolic blood pressure (SBP) at 12 weeks compared to placebo in patients with uncontrolled hypertension, according to a Late-Breaking Clinical Trial presented at ACC.25 in Chicago.
The WARRIOR trial provides insight into intensive medical therapy in women with INOCA, but investigators caution limitations hinder the applicability of results.
Extended anticoagulant therapy with a reduced-dose of apixaban was noninferior to extended therapy with a full-dose of apixaban in preventing recurrent venous thromboembolism (VTE) in patients with active cancer and proximal deep-vein thrombosis or pulmonary embolism, based on findings from the API-CAT trial presented at ACC.25 in Chicago and simultaneously published in NEJM.
The goal of the phase 3b STRIDE trial was to evaluate the safety of once-weekly injections of the GLP-1 receptor agonist semaglutide and to determine whether it improves function (symptoms and quality of life [QoL]) in patients with symptomatic peripheral artery disease (PAD) and type 2 diabetes (T2D) with functional limitations.
(MedPage Today) -- CHICAGO -- Dapagliflozin (Farxiga) lowered mortality and heart failure worsening in high-risk older adults getting transcatheter aortic valve implantation (TAVI), the DapaTAVI trial showed. In a population with a history of.
Intensive medical therapy did not significantly impact the rate of serious cardiovascular events at five years in women with suspected ischemia with nonobstructive coronary arteries (INOCA), according to researchers presenting findings from WARRIOR during a Late-Breaking Clinical Trial session at ACC.25 in Chicago.
(MedPage Today) -- TTHealthWatch is a weekly podcast from Texas Tech. In it, Elizabeth Tracey, director of electronic media for Johns Hopkins Medicine in Baltimore, and Rick Lange, MD, president of the Texas Tech University Health Sciences Center.
Semaglutide, compared to placebo, significantly improved walking distance, symptoms and quality of life in participants with symptomatic peripheral artery disease (PAD) and type 2 diabetes (T2D), according to results of the STRIDE study presented at ACC.25 in Chicago and simultaneously published in The Lancet.
(MedPage Today) -- CHICAGO -- The WARRIOR trial was not able to prove that intensive medical therapy reduced major adverse cardiovascular events (MACE) in women with ischemia but no obstructive disease. For symptomatic patients with suspected.
Panelists provide an overview of spesolimab, an IL-36R inhibitor now FDA-approved for treating GPP, discussing the efficacy and safety data from the EFFISAYIL-1 trial (intravenous [IV] formulation) and the EFFISAYIL-2 trial (subcutaneous [SQ] formulation).
(MedPage Today) -- CHICAGO -- For extended anticoagulation after venous thromboembolism (VTE) in patients with active cancer, a lower dose of apixaban (Eliquis) was just as effective as a higher dose -- and safer, the API-CAT randomized trial.
Panelists compare the results of the EFFISAYIL-1 and -2 trials with real-world use of spesolimab; discuss treatment expectations with patients; and explore the similarities, differences, and management roles of intravenous (IV) and subcutaneous (SQ) formulations, with strategies for timely IV therapy initiation during flares.
The goal of the phase 3b SOUL trial was to assess the cardiovascular efficacy of oral semaglutide, a GLP-1 receptor agonist, and to determine the risk of major adverse cardiovascular events (MACE) in patients with type 2 diabetes mellitus (T2DM) and atherosclerotic cardiovascular disease (ASCVD), chronic kidney disease (CKD), or both.
Panelists discuss spesolimabs place in therapy for treating generalized pustular psoriasis (GPP), address remaining unmet treatment needs, and share the types of future data they would like to see, along with key takeaways and advice for dermatologists managing patients with GPP.
The goal of the WARRIOR trial was to determine whether intensive medical therapy vs. usual care would reduce first occurrence of major adverse cardiovascular events (MACE) in women with ischemia and nonobstructive coronary artery disease (INOCA) at 5-year follow-up.
Circulation, Ahead of Print. Background: Symptomatic severe aortic stenosis (AS) remains undertreated with high resultant mortality despite increased growth and availability of aortic valve replacement (AVR) since the advent of transcatheter therapies. We evaluate the impact of electronic provider notifications (EPN) on rates of AVR at 1-year.Methods: In a pragmatic cluster randomized clinical trial conducted within multicenter academic health system from March 2022 through November 2023, 285 pr
The goal of the HOST-BR trial was to determine the optimal duration of dual antiplatelet therapy (DAPT) for patients who were stratified by high or low bleeding risk after receiving PCI with drug-eluting stent.
During atypical atrioventricular nodal reentrant tachycardia (AVNRT), the earliest atrial activation site following retrograde slow pathway (SP) conduction is at the atrial exit of the left inferior extension (LIE) in the coronary sinus (CS) or the right inferior extension (RIE) on the tricuspid annulus (TA).
Four-factor prothrombin complex concentrate (PCC) proved superior in both hemostatic response and safety to frozen plasma for coagulation factor replacement for bleeding during cardiac surgery, according to a Late-Breaking Clinical Trial presented at ACC.25 in Chicago and simultaneously published in JAMA.
In a randomized trial, the routine use of cerebral embolic protection during TAVI did not reduce the incidence of stroke within 72 hours or before discharge from the hospital (if discharge occurred sooner).
Artificial intelligence (AI) is revolutionizing cardiovascular medicine and it is taking center stage at ACC.25. This years two-day Intensive program showcases how this ever evolving technology can be incorporated into practice and lead to better patient care.
The ECG in Figure-1 was obtained from an older man with a history of coronary disease who presented to the ED ( E mergency D epartment ) alert, but complaining of chest tightness since the previous night. The consulting cardiologist interpreted this tracing as SVT ( S upra V entricular T achycardia ) with QRS widening due to aberrant conduction. QUESTIONS: How would YOU intepret the ECG in Figure-1 ?
The goal of the phase 2b Advance-HTN trial was to assess the 24-hour systolic blood pressure (SBP) lowering effect of lorundrostat, a novel aldosterone synthase inhibitor, taken once daily in participants with uncontrolled and treatment-resistant hypertension on a standardized antihypertensive regimen.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
75 
Let's personalize your content